Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;185(1):139-146.
doi: 10.1111/bjd.19751. Epub 2021 Feb 8.

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

K S Thomas  1 , C A Apfelbacher  2 , J R Chalmers  1 , E Simpson  3 , P I Spuls  4 , L A A Gerbens  4 , H C Williams  1 , J Schmitt  5 , M Gabes  6 , L Howells  1 , B L Stuart  7 , E Grinich  8 , T Pawlitschek  8 , T Burton  9 , L Howie  10 , A Gadkari  11 , L Eckert  12 , T Ebata  13 , M Boers  14 , H Saeki  15 , T Nakahara  16 , N Katoh  17
Affiliations

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

K S Thomas et al. Br J Dermatol. 2021 Jul.

Abstract

Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting.

Objectives: To complete the core outcome set for AE by agreeing on core outcome instruments for the domains of quality of life (QoL), long-term control and itch intensity.

Methods: A face-to-face consensus meeting was held in Tokyo, Japan (8-10 April 2019) including 75 participants (49 healthcare professionals/methodologists, 14 patients, 12 industry representatives) from 16 countries. Consensus decisions were made by presentations of evidence, followed by whole and small group discussions and anonymous voting using predefined consensus rules.

Results: It was agreed by consensus that QoL should be measured using the Dermatology Life Quality Index (DLQI) for adults, the Children's Dermatology Life Quality Index (CDLQI) for children and the Infant's Dermatology Quality of Life Index (IDQoL) for infants. For long-term control, the Recap of Atopic Eczema (RECAP) instrument or the Atopic Dermatitis Control Test (ADCT) should be used. Consensus was not reached over the frequency of data collection for long-term control. The peak itch numerical rating scale (NRS)-11 past 24 h was recommended as an additional instrument for the symptom domain in trials of older children and adults. Agreement was reached that all core outcome instruments should be captured at baseline and at the time of primary outcome assessment as a minimum.

Conclusions: For now, the core outcome set for clinical trials in AE is complete. The specified domains and instruments should be used in all new clinical trials and systematic reviews of eczema treatments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Conceptual framework for eczema control (reproduced with permission from Howells et al.14).
See this image and copyright information in PMC

Comment in

References

    1. Williamson P, Altman D, Blazeby Jet al. Driving up the quality and relevance of research through the use of agreed core outcomes. J Health Serv Res Policy 2012; 17:1–2. - PubMed
    1. Schmitt J, Spuls PI, Thomas KSet al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014; 134:800–7. - PubMed
    1. Charman CR, Venn AJ, Williams HC. The Patient‐Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004; 140:1513–19. - PubMed
    1. Spuls PI, Gerbens LAA, Simpson Eet al. Patient‐Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol 2017; 176:979–84. - PubMed
    1. Chalmers JR, Simpson E, Apfelbacher CJet al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2016; 175:69–79. - PubMed

Publication types